Scott Huennekens Named Executive Board Chairman at Elucid

Elucid Inc. has appointed Scott Huennekens as executive chairman of its Board of Directors.
 
“There are few medtech leaders with Scott’s vast experience and his particular expertise in technology characterizing vascular disease is perfectly aligned to Elucid’s mission. He has a proven track record in building innovative companies addressing large, unmet clinical needs,” Elucid CEO Blake Richards said. “Having Scott join us as executive chairman at this phase in the company’s rapid growth will be invaluable towards achieving our mission of unprecedented precision healthcare to reduce deaths from heart attack and stroke.”
 
Huennekens has more than 25 years of experience as a successful medtech CEO, chairperson, board member, entrepreneur and investor. He has held a number of executive leadership roles within the industry, including as president and CEO at Volcano Corporation, which he guided to an IPO in 2006, prior to its sale to Philips in 2015. Huennekens also served as president and CEO of Verb Surgical, a Google and J&J joint venture, and as president and CEO of Digirad Corp., a coronary imaging solutions provider. His extensive board leadership spans more than a dozen public and private companies. In total, Huennekens has held leadership roles in more than 20 startup, growth, and public companies with market valuations that have totaled more than $20 billion, including eight IPOs. More importantly, more than 20 million patients have benefited from the therapies and diagnostics of these companies.

Huennekens earned an MBA from Harvard University and a bachelor of science degree in business administration from the University of Southern California.
 
“It is an honor to join Elucid as chairman of the board of directors,” Huennekens said. “Elucid technology is a proven tool designed to advance coronary artery disease risk prediction and management in the cardiology practice. Characterizing risk of heart attack and stroke is an unmet need, and Elucid technology has the potential to change the way we diagnose patients at risk to provide a new standard of care.”
 
Elucid’s software is the only U.S. Food and Drug Administration (FDA)-cleared non-invasive tool able to accurately characterize arterial plaque, simulating what pathologists would see under a microscope and establishing a histologic ground truth. Elucid is also pursuing an indication for FFRCT, uniquely derived from its PlaqueIQ technology, to non-invasively measure coronary blockages and the extent of ischemia.
 
Huennekens’ appointment follows the recent addition of Dr. Michael Lesh to the board.
 
Elucid is a Boston-based medical technology company dedicated to bringing precision patient care to cardiology. Its AI-powered imaging analysis software is designed to deeply understand the root cause of cardiovascular disease. Elucid’s plaque analysis software is powered by PlaqueIQ, the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against tens of thousands of tissue samples by renowned pathologists. PlaqueIQ equips physicians with critical information for assessing the risk of plaque rupture in arteries that can lead to heart attack and stroke. The Elucid plaque analysis software is available for commercial use in the United States, United Kingdom, EU, and South Korea.